Role of MRAs in HFmrEF and HFpEF

September 24, 2024

Javed Butler, MD, MPH, MBA

Opinion

Video

Javed Butler, MD, MPH, MBA, discusses the current mineralocorticoid receptor antagonists (MRAs) used for heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF, emphasizing the role of nonsteroidal MRAs such as finerenone, and explore how the FINEARTS-HF results could translate into real-world benefits and inform the clinical pathway for these patients.

EP: 1.Overview of FINEARTS-HF Trial

Now Viewing

EP: 2.Role of MRAs in HFmrEF and HFpEF

EP: 3.Overview of BB Use and Outcomes in HFmrEF and HFpEF

EP: 4.Multi-Modal Treatment Strategy for HFmrEF and HFpEF

EP: 5.Unmet Needs in the HFmrEF and HFpEF Landscape

EP: 6.Overview of DAPA ECHO Trial

Video content above is prompted by the following:

Which mineralocorticoid receptor antagonists (MRAs; ie, steroidal, nonsteroidal) are currently indicated or used for treating heart failure with midrange ejection fraction (HFmrEF) and HF failure with preserved EF (HFpEF), and what role does a nonsteroidal MRA such as finerenone have to offer in this treatment landscape based on the results of FINEARTS-HF?
How might these results translate into real-world benefit, and where do you see their place in the clinical pathway for patients with HFmrEF or HFpEF?